Mitsubishi UFJ Asset Management Co. Ltd. Purchases 12,530 Shares of Biogen Inc. $BIIB

Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Biogen Inc. (NASDAQ:BIIB) by 4.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 319,909 shares of the biotechnology company’s stock after acquiring an additional 12,530 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Biogen were worth $56,886,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of BIIB. Orion Porfolio Solutions LLC lifted its stake in shares of Biogen by 6,828.4% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock valued at $64,965,000 after acquiring an additional 509,809 shares during the last quarter. Caisse de depot et placement du Quebec lifted its stake in shares of Biogen by 718.2% in the 3rd quarter. Caisse de depot et placement du Quebec now owns 569,253 shares of the biotechnology company’s stock valued at $79,741,000 after acquiring an additional 499,676 shares during the last quarter. AQR Capital Management LLC lifted its stake in shares of Biogen by 30.7% in the 3rd quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company’s stock valued at $248,809,000 after acquiring an additional 418,776 shares during the last quarter. Alyeska Investment Group L.P. lifted its stake in shares of Biogen by 66.1% in the 3rd quarter. Alyeska Investment Group L.P. now owns 845,277 shares of the biotechnology company’s stock valued at $118,406,000 after acquiring an additional 336,504 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Biogen by 425.3% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 348,404 shares of the biotechnology company’s stock valued at $48,804,000 after acquiring an additional 282,084 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: The FDA said it needs more time to review additional information for LEQEMBI IQLIK, but Biogen and Eisai said the agency has not expressed concerns about approval, keeping alive the chance of another Alzheimer’s franchise win. Article Title
• Positive Sentiment: LEQEMBI is already approved in more than 50 markets worldwide, which reinforces confidence in the therapy’s commercial potential if the FDA clears the subcutaneous starting-dose version. Article Title
• Neutral Sentiment: Wall Street analysts made several earnings estimate updates for Biogen ahead of the next quarterly results, with mixed direction across quarters; these revisions do not appear to be the main driver of the stock move today. Article Title
• Negative Sentiment: The delayed FDA review means Biogen must wait longer for a potential expansion of its Alzheimer’s treatment business, which could postpone any related sales boost. Article Title

Analyst Ratings Changes

BIIB has been the subject of a number of recent research reports. Canaccord Genuity Group boosted their target price on Biogen from $230.00 to $245.00 and gave the company a “buy” rating in a research note on Wednesday, April 1st. Wolfe Research set a $231.00 target price on Biogen in a research note on Monday, February 9th. JPMorgan Chase & Co. boosted their target price on Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a research note on Thursday, April 23rd. Morgan Stanley boosted their target price on Biogen from $200.00 to $206.00 and gave the company an “equal weight” rating in a research note on Thursday, April 30th. Finally, Oppenheimer boosted their target price on Biogen from $250.00 to $275.00 and gave the company an “outperform” rating in a research note on Wednesday, April 1st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $214.23.

Biogen Stock Up 1.1%

BIIB stock opened at $193.45 on Friday. Biogen Inc. has a fifty-two week low of $118.05 and a fifty-two week high of $202.41. The business’s 50 day moving average price is $184.27 and its two-hundred day moving average price is $177.50. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. The company has a market capitalization of $28.56 billion, a price-to-earnings ratio of 20.76, a price-to-earnings-growth ratio of 1.67 and a beta of 0.19.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping the consensus estimate of $2.95 by $0.62. The company had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The firm’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, analysts forecast that Biogen Inc. will post 14.31 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Biogen news, insider Priya Singhal sold 2,660 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the sale, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.18% of the company’s stock.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.